Lacuna

Lacuna is a San Francisco-based biotechnology company focused on overcoming the blood-brain barrier (BBB) to enable the delivery of therapeutics to the central nervous system. The company utilizes a proprietary discovery platform that combines high-resolution molecular mapping with functional genomics to identify novel transport receptors and pathways. By leveraging these insights, Lacuna aims to develop a pipeline of highly brain-penetrant medicines, primarily monoclonal antibodies, for the treatment of neurodegenerative diseases and neuro-oncology. The company is currently in the pre-clinical stage and is backed by prominent life science investors including Lux Capital and Polaris Partners.